Drugs / Gemini
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06863467 | Jan → Jul 2025 | chronic kidney disease | Revelation Biosciences, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gemini | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06863467 ↗ |
| Route | Intravenous | “Single ascending intravenous dose infused once over 10-15 minutes.” NCT06863467 ↗ |